These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 21810665)

  • 1. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.
    Thadhani R; Kisner T; Hagmann H; Bossung V; Noack S; Schaarschmidt W; Jank A; Kribs A; Cornely OA; Kreyssig C; Hemphill L; Rigby AC; Khedkar S; Lindner TH; Mallmann P; Stepan H; Karumanchi SA; Benzing T
    Circulation; 2011 Aug; 124(8):940-50. PubMed ID: 21810665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.
    Thadhani R; Hagmann H; Schaarschmidt W; Roth B; Cingoez T; Karumanchi SA; Wenger J; Lucchesi KJ; Tamez H; Lindner T; Fridman A; Thome U; Kribs A; Danner M; Hamacher S; Mallmann P; Stepan H; Benzing T
    J Am Soc Nephrol; 2016 Mar; 27(3):903-13. PubMed ID: 26405111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study.
    Winkler K; Contini C; König B; Krumrey B; Pütz G; Zschiedrich S; Pecks U; Stavropoulou D; Prömpeler H; Kunze M; Markfeld-Erol F
    Pregnancy Hypertens; 2018 Apr; 12():136-143. PubMed ID: 29858106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic plasma exchange and dextran-sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restriction.
    Gubensek J; Ponikvar R; Premru Srsen T; Fabjan Vodusek V; Moertl MG; Lucovnik M
    J Clin Apher; 2021 Aug; 36(4):595-605. PubMed ID: 33847403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks' gestation.
    Nakakita B; Mogami H; Kondoh E; Tsukamoto T; Yanagita M; Konishi I
    J Obstet Gynaecol Res; 2015 Oct; 41(10):1661-3. PubMed ID: 26094569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic blood purification-based soluble fms-like tyrosine kinase-1 removal in comparison with dextran sulfate apheresis and therapeutic plasma exchange.
    Rduch T; Arn N; Kinkel J; Fischer T; Binet I; Hornung R; Herrmann IK
    Artif Organs; 2023 Aug; 47(8):1309-1318. PubMed ID: 36995348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia.
    Trapiella-Alfonso L; Alexandre L; Fraichard C; Pons K; Dumas S; Huart L; Gaucher JF; Hebert-Schuster M; Guibourdenche J; Fournier T; Vidal M; Broutin I; Lecomte-Raclet L; Malaquin L; Descroix S; Tsatsaris V; Gagey-Eilstein N; Lecarpentier E
    Hypertension; 2019 Jul; 74(1):145-153. PubMed ID: 31079531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apheresis to Treat Preeclampsia: Insights, Opportunities and Challenges.
    Easterling TR
    J Am Soc Nephrol; 2016 Mar; 27(3):663-5. PubMed ID: 26405110
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter by Espinoza regarding article, "Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia".
    Espinoza J
    Circulation; 2012 Mar; 125(12):e521; author reply e523-4. PubMed ID: 22451614
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trial.
    Haddad B; Lefèvre G; Rousseau A; Robert T; Saheb S; Rafat C; Bornes M; Petit-Hoang C; Richard F; Lecarpentier E; Tsatsaris V; Guibourdenche J; Corchia A; Rondeau E; Simon T; Hertig A
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():70-74. PubMed ID: 30326377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter by Winkler et al regarding article, "Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia".
    Winkler K; Hoffmann MM; Pütz G
    Circulation; 2012 Mar; 125(12):e522; author reply e523-4. PubMed ID: 22451615
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia, and normal pregnancy.
    Aldika Akbar MI; Herdiyantini M; Aryananda RA; CIninta N; Wardhana MP; Gumilar KE; Wicaksono B; Ernawati ; Sulistyono A; Aditiawarman ; Joewono HT; Nadir Abdullah ; Dekker G; Dachlan EG; Dikman Angsar M
    Hypertens Pregnancy; 2018 Nov; 37(4):175-181. PubMed ID: 30277426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
    Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
    Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
    Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
    Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
    BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.